Corgi | $108,000,000 | (Jan 9, 2026)
Corsera Health | $80,000,000 | (Jan 9, 2026)
Oasys | $4,600,000 | (Jan 9, 2026)
Predicta Biosciences
United States
- Cambridge, Massachusetts
- 17/07/2024
- Seed
- $5,200,000
Predicta Biosciences is a precision oncology company integrating cutting edge multiomics and liquid biopsies to develop innovative diagnostic and therapeutic products. Predicta's diagnostic product portfolio removes the burden of bone-marrow biopsies, through small blood-based samples, and enables best-in-class treatment decision-making for immunotherapies. Utilizing the data from the diagnostic platform, Predicta has an in-house therapeutic pipeline of novel immunotherapy targets in pre-clinical discovery and development.
- Industry Biotechnology Research
- Website https://www.predictabiosciences.com/
- LinkedIn https://www.linkedin.com/company/predicta-biosciences/
Related People
Kate (Gallagher) CavesFounder
United States -
Greater Boston
Executive Leader with Business Development, Corporate Development, Marketing and deep technical background in Therapeutic Development and Diagnostic tools. Passionate about the intersection of Biology, Healthcare, and AI.
Vizgen | $48,000,000 | (Jan 9, 2026)
Poplar Therapeutics | $50,000,000 | (Jan 9, 2026)
Valinor(US) | $54,000,000 | (Jan 9, 2026)
Alveus Therapeutics Inc | $160,000,000 | (Jan 9, 2026)
AgileRL | $7,500,000 | (Jan 9, 2026)
Soley Therapeutics | $200,000,000 | (Jan 9, 2026)
EpiBiologics | $107,000,000 | (Jan 9, 2026)